2 Small-Cap Healthcare Stocks Wall Street Predicts Will Rally by More Than 200%

: BYSI | BeyondSpring, Inc. - Ordinary Shares News, Ratings, and Charts

BYSI – The healthcare industry is expected to witness increasing demand amid an aging population. As such, Wall Street analysts expect small-cap healthcare stocks BeyondSpring (BYSI) and SCYNEXIS (SCYX) to gain significantly in the coming months. So, it could be wise to add these two stocks to one’s watch list. Read on.

The healthcare industry continues to enjoy immense investor attention, thanks partly to the resurgence of COVID-19 cases and the identification and effects of new variants of the deadly virus. Investors’ interest in the healthcare stocks is evident in the Health Care Select Sector SPDR Fund’s (XLV) 9.5% returns over the past three months.

Also, an aging population and relatively inelastic demand for healthcare products and services are expected to boost the industry’s growth. Total U.S. healthcare spending is expected to be $10.43 trillion this year.

Wall Street analysts expect small-cap healthcare stocks BeyondSpring Inc. (BYSI) and SCYNEXIS, Inc. (SCYX) to rally significantly in the near term. So, we think it could be wise to add the stocks to one’s watch list.

Click here to checkout our Healthcare Sector Report for 2021

BeyondSpring Inc. (BYSI)

BYSI is a clinical-stage biopharmaceutical company in New York City that develops innovative immuno-oncology cancer therapies. It has a market capitalization of $1.08 billion. Also, its lead asset, plinabulin, is in two phase 3 global clinical trials as a direct anticancer agent in treating non-small cell lung cancer (NSCLC) and preventing chemotherapy-induced neutropenia (CIN).

On August 26, 2021, BYSI formed an exclusive commercial collaboration with China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. to produce plinabulin. This is expected to help increase the company’s revenue in the near term.

BYSI’s total revenue came in at $338,000 for its fiscal first quarter, ended March 31, 2021. Its net loss was  $16.08 million, versus  $16.99 in the year-ago period. Also, its loss per share was  $0.44 compared to $0.58 in the prior-year period. However, its total liabilities decreased 14.6% sequentially to $21.53 million.

For its fiscal year 2022, analysts expect BYSI’s revenue to be $105.49 million, representing a 20,998% year-over-year rise. The company’s EPS is expected to increase 75.8% year-over-year in fiscal 2022. In addition, it surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past month, the stock has gained 189.8% in price to close yesterday’s trading session at $27.59. Wall Street analysts expect the stock to hit $97.50 in the near term, which indicates a potential 253.45 upside.

SCYNEXIS, Inc. (SCYX)

With a market capitalization of $147.43 million, SCYX is a biotechnology company delivering fungal infections treatment. Its lead product, ibrexafungerp, is being formalized as a novel oral and intravenous drug to treat various fungal infections. SCYX is based in Jersey City, N.J.

SCYX announced on June 2, 2021, that the U.S. FDA had approved BREXAFEMME (ibrexafungerp tablets) for oral use in patients with vulvovaginal candidiasis (VVC). In addition, this drug represents the first approved drug in a novel antifungal class in more than 20 years.

For the second quarter, ended June 30, 2021, SCYX’s net income came in at $1.66 million compared to a $6.38 million loss in the year-ago period. Its loss per share decreased 65.6% year-over-year to $0.22. Also, its total assets were$121.13 million for the period ended June 30, 2021, compared to $102.54 million for the period ended December 31, 2020.

Analysts expect SCYX’s revenue to increase 132% year-over-year to $28.56 million in its fiscal year 2022. Its EPS is expected to increase 20.7% year-over-year in the next year. In addition, it surpassed the Street’s EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 9.5% in price to close yesterday’s trading session at $6.35. Wall Street analysts expect the stock to hit $21.50 in the near term, which indicates a potential 238.6% upside.

Click here to checkout our Healthcare Sector Report for 2021


BYSI shares were trading at $30.65 per share on Tuesday morning, up $3.06 (+11.09%). Year-to-date, BYSI has gained 151.23%, versus a 21.74% rise in the benchmark S&P 500 index during the same period.


About the Author: Manisha Chatterjee


Since she was young, Manisha has had a strong interest in the stock market. She majored in Economics in college and has a passion for writing, which has led to her career as a research analyst. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
BYSIGet RatingGet RatingGet Rating
SCYXGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Stocks to Fall MUCH FURTHER this Bear Market Cycle

Spoiler alert...the bear market is not over. Unfortunately history shows that the S&P 500 (SPY) has much further to fall to squeeze out excess valuation. That is just a natural part of the bear market process that is properly explained in this timely market commentary. More importantly, this commentary provides a strategy on how to profit in the days and weeks ahead as the market finds its way to bottom. Read on below for more...

:  |  News, Ratings, and Charts

3 Tech Stocks to Buy as Inflation Expectations Ease

With the economy slowing and oil prices down by about 20% over the last couple of weeks, odds are increasing that inflation could be turning lower. This could be a catalyst for high-quality tech stocks such as Microsoft (MSFT), Veeva (VEEV), and Expedia (EXPE).

:  |  News, Ratings, and Charts

Don’t Get Fooled by the Recent Market Rally

The S&P 500 (SPY) has bounced with gusto this week. Maybe the bear market is not here to stay? Ha! Don't make me laugh. This is just one in a long line of "suckers rallies" before the next leg lower. The reasons why are spelled out below in this week's market commentary...

:  |  News, Ratings, and Charts

Buy These Stock Splits as Analysts See Upside

The market has witnessed several stocks-splits this year. Analysts see upside in Fortinet (FTNT), Alphabet (GOOGL), and Nintendo (NTDOY), which have either undergone a stock split or will do so in the near term. The availability of these stocks at affordable prices after their splits could be an excellent opportunity to invest in them. Continue reading…

:  |  News, Ratings, and Charts

Don’t Get Fooled by the Recent Market Rally

The S&P 500 (SPY) has bounced with gusto this week. Maybe the bear market is not here to stay? Ha! Don't make me laugh. This is just one in a long line of "suckers rallies" before the next leg lower. The reasons why are spelled out below in this week's market commentary...

Read More Stories

More BeyondSpring, Inc. - Ordinary Shares (BYSI) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All BYSI News